Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

BMY

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

BMY

AI Research Report

Powered by Claude

Ready to analyze BMY

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Healthcare →
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
JNJ
Johnson & Johnson
—
—
TMO
Thermo Fisher
—
—
WELL
Welltower
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Bristol-Myers Squibb Co

Bristol-Myers Squibb Co

Pharmaceuticals·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1980-03-17
📅 Earnings in 16d (Apr 30)
NEW YORK STOCK EXCHANGE, INC.After-hours
Bristol-Myers Squibb Co
Pharmaceuticals
—
— (—)
Open
—
Prev close
—
Day range
— – —
52W range
$42.52 – $62.89
Mkt cap
$118.54B
P/E
16.9
EPS
$3.46
Beta
0.26

Fundamentals

Valuation
Market Cap
$118.54B
P/E (TTM)
16.87S&P avg ~22
P/S (TTM)
2.47S&P avg ~2.8
P/B
5.94S&P avg ~4.5
P/FCF
9.27S&P avg ~26
EPS (TTM)
$3.46
Book/sh
$9.18
Cash/sh
$5.30
Profitability
Gross Margin
72.63%avg ~45%
Operating Margin
21.51%avg ~15%
Net Margin
14.64%avg ~12%
ROE
39.28%avg ~18%
ROA
7.54%avg ~7%
ROI
10.66%
Payout Ratio
71.51%
FCF/sh
—
Growth & Health
Rev Growth YoY
-0.22%
Rev Growth 5Y
2.54%
EPS Growth YoY
—
EPS Growth 5Y
—
Current Ratio
—
Quick Ratio
1.14
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.26
52W High
$62.89
52W Low
$42.52
Avg Vol (10D)
10.88M
Avg Vol (3M)
13.90M
Div Yield
4.34%
Div/sh (TTM)
—
Analyst
Buy (36)
Price Performance
5D+0.68%
MTD-4.27%
3M+3.86%
6M+28.62%
YTD+7.64%
1Y+15.06%

Factor Grades

View details →
B-
Overall score: 63/100
B
Valuation
D+
Growth
B+
Profitability
B-
Momentum
B
Financial Health
  • Yahoo·8h ago

    Johnson & Johnson Financial Chief Sees ‘Clear Line of Sight’ to Double-Digit Growth by 2030

    Johnson & Johnson has reinvented itself several times in recent years. Its latest earnings report signals the company has reinvented itself again. J&J posted adjusted earnings of $2.70 a share for the first quarter, narrowly beating out the $2.68 a share analysts had anticipated.

  • Yahoo·11h ago

    Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter.

    Johnson & Johnson has reinvented itself several times in recent years. J&J posted adjusted earnings of $2.70 a share for the first quarter, narrowly beating out the $2.68 a share analysts had anticipated. Sales grew by more than 11% in J&J’s Innovative Medicine arm, which includes its oncology portfolio, and 7.7% in its medical technology division.

  • Yahoo·12h ago

    Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter.

    Johnson & Johnson stock gained on Tuesday after the pharmaceutical giant and medical device maker posted better-than-expected earnings and flagged strong sales growth in its first quarter. J&J posted adjusted earnings of $2.70 a share for its latest quarter, narrowly beating out the $2.68 a share analysts had anticipated. For the full year, J&J is targeting adjusted earnings of $11.45 to $11.65 a share, up slightly from a prior range of $11.43 to $11.63 a share.

  • Yahoo·1d ago

    Is Bristol-Myers Squibb Company (BMY) Among the 15 Cash-Rich Dividend Stocks to Invest in Right Now

    Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Cash-Rich Dividend Stocks to Invest in Right Now. On April 9, BofA analyst Jason Gerberry lowered the price recommendation on Bristol-Myers Squibb Company (NYSE:BMY) to $67 from $68. It reiterated a Buy rating on the shares. The firm made several adjustments alongside its Q1 preview for […]

  • Yahoo·1d ago

    Johnson & Johnson Earnings Are Coming. Oncology Powers Growth, but Talc Lawsuits Persist.

    Johnson & Johnson has reinvented itself several times in recent years. In 2023, it spun off its consumer health division to focus on pharmaceuticals and medical devices. J&J may signal yet another iteration when first-quarter earnings are posted before the market opens Tuesday.

  • Yahoo·1d ago

    Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist

    Johnson & Johnson has reinvented itself several times in recent years. In 2023, it spun off its consumer health division to focus on pharmaceuticals and medical devices. J&J may signal yet another iteration when first-quarter earnings are posted before the market opens Tuesday.

  • CNBC·1d ago

    Jim Cramer says this is the real reason why stocks are shrugging off Iran war fears

    "If interest rates were spiking, this market would be very different," CNBC's Jim Cramer said Monday.

  • Yahoo·1d ago

    Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.

    Shares of Replimune Group receive multiple downgrades after the Food and Drug Administration twice rejects its experimental cancer drug.

  • View all news →
⚠️
Dilution risk detected

3 offering-related filings in the last 60 filings. Latest: 424B5 on 2025-11-07. View all →

Recent insider activity

View all →
  • 4FORM 4
    12d ago
  • 4FORM 4
    12d ago
  • 4FORM 4
    12d ago
  • 4FORM 4
    12d ago
  • 4FORM 4
    12d ago